Open House Discount Agreement Erythropoietin alfa
Titre original de l'avis
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Erythropoietin alfa, ATC B03XA01
Score d'opportunité
Pourquoi ce score ?
Opportunité
60 / 100
Complexité
20 / 100
Facteurs de risque
No estimated value or volume commitment; actual business may be minimal.
Open house model is not subject to procurement law; legal remedies are via social courts, not procurement chambers.
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Strong opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Aug 2027
- Non-exclusive discount agreement for Erythropoietin alfa (ATC B03XA01) with AOK Bayern
- Supply of pharmaceutical products containing the active substance Erythropoietin alfa
Afficher le résumé complet
Open house non-exclusive discount agreement for the pharmaceutical product Erythropoietin alfa (ATC B03XA01) with AOK Bayern. All interested pharmaceutical companies meeting eligibility criteria can conclude identical, non-negotiable discount agreements. Contracts run from 1 September 2025 to 31 August 2027, with possible termination. This is not a classic procurement procedure but a non-exclusive open-house model under §130a SGB V. No estimated value is published.
Risques
No estimated value or volume commitment; actual business may be minimal.
Open house model is not subject to procurement law; legal remedies are via social courts, not procurement chambers.
Exigences clés
Eligibility
- Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible to participate
Administrative
- Submission of a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
- Submission of the signed contract including the completed appendix 'Festlegung der vertragsgegenständlichen Arzneimittel'
Les exigences peuvent être incomplètes.
Critères d'attribution
Lot 1
Acheteur
Localisation
München, DEU
Site web
Profil acheteur
Identifiant
DE811695320
Activité
Health
Lots (1)
LOT-0001
Open House Discount Agreement Erythropoietin alfa
Single lot covering the active substance Erythropoietin alfa. All interested pharmaceutical companies that meet the eligibility criteria can conclude the same discount agreement. The contract can be concluded at any time during the term, latest by 3 July 2027. Submission must be via the communication area of the dtvp portal (not the offer area) or by post with specific deadlines.
Localisation
Durée
Catégorie
Critères d'attribution
Date limite
Détails des critères
Not applicable – open house model, no selection or award criteria. Any eligible company can join.
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Open house Arzneimittelrabattverträge Erythropoietin alfa, ATC B03XA01
Description TED originale
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Détails de la procédure
- Date de publication
- 13 Jul 2025
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 458024-2025
Documents (2)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
60 / 100
Complexité
20 / 100
Facteurs de risque
No estimated value or volume commitment; actual business may be minimal.
Open house model is not subject to procurement law; legal remedies are via social courts, not procurement chambers.
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications